EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


May 22–23, 2017
Ronald Reagan Building,
Washington, DC

Thank you for attending Cell & Gene Exchange

A partnering forum focused on the regulatory, business, and patient advocate communities in cell and gene therapy sectors.

Stay tuned for updates on the 2018 event.

Read the Scrip article

“Patient Group Collaboration In Rare Diseases Offers Model For Cell/Gene Therapy Firms”

Conference Highlights

Company presentations

Opportunities to engage with partners

One-to-one meetings

Connect with potential partners with the world's leading web-based partnering system, partneringONE®.

Showcase your company

Leading biotech companies and patient advocacy group will highlight their partnering opportunities through company presentations.

Elevate your brand

Sponsor or exhibit to position your company among the innovators at Cell & Gene Exchange.

Event and community news

Get the latest news and gain an in-depth look at the people and topics behind life science partnering.

Partnerships are key for rare disease drug discovery and development

What kinds of partnerships are key to getting rare disease research out of the lab and to patients as therapies and cures? Wendy White, Board Chairman of Global Genes, discusses her work on behalf of the leading global rare disease patient advocacy organization, and the impact patient advocacy groups are making on rare disease research at BIO-Europe Spring 2017 in Barcelona, Spain.

Presenting at Cell & Gene Exchange


Gold Sponsors

Silver Sponsors

Bronze Sponsors


The Cell & Gene Exchange brings together leaders from patient advocacy groups, industry, academia and government to network, exchange ideas and explore partnership opportunities. The goal is facilitating conversations among patient groups and key stakeholders to advancing potentially curative therapies for life-threatening diseases.